<<it appears to me that the two technologies are complementary.>>
If they are complementary, then my comments regarding CDIC's exclusion of mention of the CVProfilor remain intact, reinforced. The reference group, to repeat, is NOT, 'traditional management by high blood pressure specialist physicians' but a screening device such as HDII's CVProfilor which is of equal, if not greater, value.
<< I doubt that with hypertensive medication one would expect to see changes in arterial elasticity...>>
I understand neither the basis nor the logic supporting that statement.
We have all learned over the past two years that company officers and/or investors with a financial stake internet firms, energy trading outfits, and all flavors of biotechnology/medical device makers will make preposterous claims of their products. These 'communicators' will make seemingly humble statements, or pose premise-filled, seemingly innocent questions...that are none of the above.
To whit, what is your knowledge of cardiovascular biochemistry that allows you to assume, in the form of a question, that hypertensive medication would lead to changes in cardiac output and not arterial elasticity?
In fact, if pondered for a nanosecond, your presumption is absurd: if you change cardiac output, it would seem fully logical that the autonomic response would be to compensate for the change in output. Increase output, the body responds by increasing elasticity (to account for the greater blood volume).
And vice versa.
Thus the essential common denominator is PRECISELY what HDII's CVProfilor measures: the elasticity of the peripheral vasculature ..which is, needless to say, the essence of 'blood pressure'.
The conclusion is that the CVProfilor is better 'positioned' than Biowhatever of CDIC. |
